Nuveen Asset Management LLC Sells 232,335 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Nuveen Asset Management LLC decreased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 11.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,798,989 shares of the biopharmaceutical company's stock after selling 232,335 shares during the quarter. Nuveen Asset Management LLC owned 1.16% of TG Therapeutics worth $54,150,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Quadrant Capital Group LLC raised its position in shares of TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 975 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 1,737 shares during the last quarter. Finally, Synergy Asset Management LLC acquired a new stake in shares of TG Therapeutics during the 4th quarter worth $75,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Price Performance

TG Therapeutics stock traded up $0.33 during mid-day trading on Friday, hitting $34.57. The company's stock had a trading volume of 1,042,767 shares, compared to its average volume of 2,989,933. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $5.49 billion, a P/E ratio of -345.67 and a beta of 2.21. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The stock's fifty day moving average price is $38.13 and its two-hundred day moving average price is $34.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same quarter in the previous year, the firm posted ($0.07) earnings per share. The company's revenue for the quarter was up 90.4% on a year-over-year basis. Research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Ratings Changes

TGTX has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.